Health Insurance - Workgroup to Study the Definition of Specialty Drug

Summary

The Maryland Insurance Administration must convene a workgroup that includes pharmacy‑benefit managers, independent pharmacists, insurers, a managed‑care organization, a hospital and another health‑care provider. The group will examine the current specialty‑drug definition, assess its impact on patients and other stakeholders, compare it to definitions used elsewhere, and propose a new definition. Their findings are to be reported to the governor and General Assembly, and the law ends on June 30 2027.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share